News

LaVoieHealthScience Announces New PR Clients to its Roster

BOSTON, MA – March 23, 2017 – LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced it has signed new clients to its public relations client roster including BioAxone BioSciences, Inc.,  “Our passion is to represent true innovators in the health and science fields,” said Donna L….

Posted in News | Tagged , , , , , , , , , , , , , , | Comments Off on LaVoieHealthScience Announces New PR Clients to its Roster

Spotlight: Q&A with Michael Almstetter, CEO, Origenis

Michael Almstetter CEO Q: What does Origenis do? A: Origenis is creating small molecule drugs capable of penetrating the blood-brain barrier and therefore treating neurodegenerative diseases – commonly known as Central Nervous System, or CNS, diseases. Our technology-based drug design process develops faster, more specific compounds. I am pleased to note our platform has been…

Posted in News | Tagged , , , , , , , , , , , | Comments Off on Spotlight: Q&A with Michael Almstetter, CEO, Origenis

LaVoieHealthScience Awarded MarCom Gold for Oticon Opn™ Launch

Boston, Mass., – November 8, 2016 – LaVoieHealthScience (LHS), an integrated strategic communications agency focused on health and life science, announced today it has won a MarCom Gold Award in the product launch category for the agency’s work on the Opn™ launch on behalf of its client, Oticon, an advanced audiology and hearing aid technology…

Posted in News | Comments Off on LaVoieHealthScience Awarded MarCom Gold for Oticon Opn™ Launch

LaVoieHealthScience Celebrates 15 Years of Client Service to the Health & Science Industry By Supporting Advances in Cancer

LHS team fundraises at Jimmy Fund events and participates in their Strike Out for Cancer Initiative by donating to Dana-Farber Cancer Institute in Support of Oncology Research and Care BOSTON, MASS. – October 26, 2016 – LaVoieHealthScience (LHS), an integrated strategic communications agency focused on health and life science, is celebrating its 15th anniversary in…

Posted in News | Comments Off on LaVoieHealthScience Celebrates 15 Years of Client Service to the Health & Science Industry By Supporting Advances in Cancer

Medicinal Genomics Uses DNA Sequencing on their Strands of Marijuana

Woburn company applies DNA sequencing to budding marijuana industry   By: Jessica Bartlett October 6, 2016 From Purple Haze to Orange Crush, the names given to different strains of marijuana are colorful, and largely just based on where the plant is grown or what people experience when smoking it. But with medical marijuana’s recent legalization…

Posted in News | Tagged , , , , , | Comments Off on Medicinal Genomics Uses DNA Sequencing on their Strands of Marijuana

NewLink Receives Funds for Research on Ebola Vaccine V920

Feds help NewLink, Merck out with some added cash for Ebola vaccine   By: Arsalan Arif October 6, 2016 Two months after NewLink was forced to restructure and slash staff in the wake of a Phase III debacle on pancreatic cancer, the Ames, IA-based biotech and its Big Pharma partner Merck can celebrate some added…

Posted in News | Comments Off on NewLink Receives Funds for Research on Ebola Vaccine V920

LEO Pharma Expands Partnering Presence with LEO Science & Tech Hub in Boston

LEO Pharma grabs toehold in Cambridge   By: Robert Weisman September 29, 2016 Denmark’s LEO Pharma is the latest European health care company to open an office in Cambridge’s Kendall Square, a global life sciences hub. The company, owned by the LEO Foundation based in the Danish town of Ballerup, plans to announce Friday that…

Posted in News | Comments Off on LEO Pharma Expands Partnering Presence with LEO Science & Tech Hub in Boston

Donna LaVoie to Deliver Workshop at BioPharm America on How and When to Form a Corporate Board

Boston – September 14, 2016 – Donna LaVoie, president and CEO of LaVoieHealthScience (LHS), an award winning strategic communications agency focused on health and life science, will be a featured speaker on Wednesday, September 14, at the BioPharm America’s 9th Annual International Partnering Conference to be held in Boston. BioPharm America provides a unique venue…

Posted in News | Comments Off on Donna LaVoie to Deliver Workshop at BioPharm America on How and When to Form a Corporate Board

Big3Bio Spotlights Q&A with Ian Chan, CEO & Founder, Abpro

      About Abpro Abpro is an integrated life science company focused on industrial biochemistry. Through its DiversImmune™ platform, Abpro leverages synthetic biology and immunology to create novel biomolecules for use in research, diagnostics, animal health and therapeutics. Abpro’s platform has been validated by major pharmaceutical, biotechnology and academic labs around the world. What…

Posted in News | Tagged , , , , , , , , , , , , | Comments Off on Big3Bio Spotlights Q&A with Ian Chan, CEO & Founder, Abpro

Life Science Leader Features Stefan Weber, CEO of Newron Pharmaceuticals SpA, on Drug Company Discovery & Commercialization

Drug Company Discovery & Commercialization: An Election Year Analogy By Stefan Weber, CEO and Executive Director, Newron Pharmaceuticals SpA When smaller, boutique drug companies move from precommercial discovery to postcommercial marketing, they can experience a shock. Precommercial work is typically rigorous and controlled with trials conducted in sequential fashion and oversight done by recognized governing…

Posted in News | Tagged , , , , , , , , , , , , | Comments Off on Life Science Leader Features Stefan Weber, CEO of Newron Pharmaceuticals SpA, on Drug Company Discovery & Commercialization

Event Calendar

LavoieHealthScience Blog

After the Conference: Four Fundamental Follow-Throughs

Conferences are all-important opportunities for in-person conversations with investors, partners, prospects and others. Gearing up, scheduling meetings and ensuring up-to-date materials can absorb a lot of bandwidth in advance of the conference itself. However, unless you commit to spending an equal amount of time after the conference to follow through, the time spent up front…

Posted in LavoieHealthScience Blog | Tagged , , , , , , , , , , , , | Comments Off on After the Conference: Four Fundamental Follow-Throughs

And the Winner is…. The Value of Awards

Did you watch the Academy Awards?  Regardless, I bet you know that Moonlight (eventually) won best picture and Emma Stone won best actress.   While accepting a health science award may not offer the same red carpet experience and drama, the opportunity for recognition is one that should not be overlooked.  As such, we recommend life and…

Posted in LavoieHealthScience Blog | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on And the Winner is…. The Value of Awards

So Many Data Slides, So Little Time

We see a lot of scientific data slides – data on animal studies, MOAs, clinical data and more. Alas, with so many data slides, the impact can get subsumed. Audiences are interested in the underlying science or clinical trials, but they’re also interested in the overarching story – what is the problem being solved, why…

Posted in LavoieHealthScience Blog | Tagged , , , , , , , , , , , | Comments Off on So Many Data Slides, So Little Time

How and When to Build a Board: A Primer for Health & Science Emerging Companies

How many people, when to recruit and what kind of strategy?  It depends. That’s the only answer that applies across all health science emerging companies considering formation of a board.  Board directors serve a variety of roles: they provide strategic decision-making; set operational and performance metrics for the company; provide access to capital; and provide…

Posted in LavoieHealthScience Blog | Tagged , , , , , , , , , , , | Comments Off on How and When to Build a Board: A Primer for Health & Science Emerging Companies

Three Tips to Start the New Year

Starting the new year off right is important. Here are three tips to keep you on track through 2017: Strategize for the upcoming year. With so many conferences happening worldwide, this is the time to plan which one(s) are right for your company this year. These are great opportunities to connect with appropriate audiences and…

Posted in LavoieHealthScience Blog | Tagged , , , , , , , , , , , | Comments Off on Three Tips to Start the New Year

10 Top J.P. Morgan Survival Tips

Start now.  Start reaching out to those you want to meet with, with an up-to-date message and an appropriate presentation. Spread the net wide.  Extend your reach and target 20% new names.  Not sure how you’ll find them?  Try meet.bio – a dedicated platform for those who plan to be in San Francisco. Check your…

Posted in LavoieHealthScience Blog | Comments Off on 10 Top J.P. Morgan Survival Tips

Paper or Pixels? We’ll Take Both Please

It’s one thing to be environmentally conscious, but another to give an Investor Relations presentation without offering any type of hard copy collateral. In a move to “go green,” some are choosing to offer USB sticks, others are simply not handing out any material at all. But this is a mistake. The hand-out need not…

Posted in LavoieHealthScience Blog | Comments Off on Paper or Pixels? We’ll Take Both Please

LHS IR Spot – Managing an IR Database: FOMO vs. TMI

FOMO (Fear of Missing Out) is real in the IR business. Did you miss a Boston investor who asked for a 1:1 the next time you’re in town? Did you forget that great question asked by a San Francisco-based analyst? But try to capture too much intelligence, and you wind up with TMI (Too Much…

Posted in LavoieHealthScience Blog | Comments Off on LHS IR Spot – Managing an IR Database: FOMO vs. TMI

Not so Fast: Using a Media Embargo for Enhanced Coverage

In this age of “always on” media coverage, it’s interesting to review the use of the “not so fast” media embargo. For those unfamiliar with this methodology, a media embargo involves sending a press release to a reporter “under embargo.” The reporter agrees not to write on the news before it is distributed across the…

Posted in LavoieHealthScience Blog | Comments Off on Not so Fast: Using a Media Embargo for Enhanced Coverage

Scenario Analysis Planning for Phase III Results

3 Scenarios, 2 Months, 1 Message   Phase III data lock in sight? Your internal scenario analysis starts now. That’s three scenarios, two months in advance, one unified message. The three scenarios may be overwhelming efficacy, modest efficacy and insufficient efficacy. Each scenario analysis should consider the primary endpoint data, preliminary views, interpretation of the…

Posted in LavoieHealthScience Blog | Comments Off on Scenario Analysis Planning for Phase III Results

Event Calendar

Event Calendar

Event Calendar

Our event calendar includes investor, medical and partnering events that take place over the course of the year.

Sun Mon Tue Wed Thu Fri Sat
1
ENDO 2017
ENDO 2017
Apr 1 – Apr 4 all-day
 
2
4
Europe MedTech 2017
Europe MedTech 2017
Apr 4 – Apr 6 all-day
 
6
8
9
12
13
14
15
16
17
20
23
27